Signaling Circuits and Regulation of Immune Suppression by Ovarian Tumor-Associated Macrophages

被引:18
作者
Cannon, Martin J. [1 ]
Ghosh, Debopam [1 ]
Gujja, Swetha [2 ]
机构
[1] Univ Arkansas Med Sci, Dept Microbiol & Immunol, 4301 W Markham, Little Rock, AR 72205 USA
[2] Univ Arkansas Med Sci, Dept Internal Med, Little Rock, AR 72205 USA
来源
VACCINES | 2015年 / 3卷 / 02期
关键词
ovarian cancer; macrophages; dendritic cells; regulatory T cells; indoleamine; 2; 3-dioxygenase; aryl hydrocarbon receptor; c-KIT; STAT3;
D O I
10.3390/vaccines3020448
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
The barriers presented by immune suppression in the ovarian tumor microenvironment present one of the biggest challenges to development of successful tumor vaccine strategies for prevention of disease recurrence and progression following primary surgery and chemotherapy. New insights gained over the last decade have revealed multiple mechanisms of immune regulation, with ovarian tumor-associated macrophages/DC likely to fulfill a central role in creating a highly immunosuppressive milieu that supports disease progression and blocks anti-tumor immunity. This review provides an appraisal of some of the key signaling pathways that may contribute to immune suppression in ovarian cancer, with a particular focus on the potential involvement of the c-KIT/PI3K/AKT, wnt/-catenin, IL-6/STAT3 and AhR signaling pathways in regulation of indoleamine 2,3-dioxygenase expression in tumor-associated macrophages. Knowledge of intercellular and intracellular circuits that shape immune suppression may afford insights for development of adjuvant treatments that alleviate immunosuppression in the tumor microenvironment and enhance the clinical efficacy of ovarian tumor vaccines.
引用
收藏
页码:448 / 466
页数:19
相关论文
共 96 条
  • [1] IL6-STAT3-HIF Signaling and Therapeutic Response to the Angiogenesis Inhibitor Sunitinib in Ovarian Clear Cell Cancer
    Anglesio, Michael S.
    George, Joshy
    Kulbe, Hagen
    Friedlander, Michael
    Rischin, Danny
    Lemech, Charlotte
    Power, Jeremy
    Coward, Jermaine
    Cowin, Prue A.
    House, Colin M.
    Chakravarty, Probir
    Gorringe, Kylie L.
    Campbell, Ian G.
    Okamoto, Aikou
    Birrer, Michael J.
    Huntsman, David G.
    de Fazio, Anna
    Kalloger, Steve E.
    Balkwill, Frances
    Gilks, C. Blake
    Bowtell, David D.
    [J]. CLINICAL CANCER RESEARCH, 2011, 17 (08) : 2538 - 2548
  • [2] The Wnt/β-catenin pathway in ovarian cancer: A review
    Arend, Rebecca C.
    Londono-Joshi, Angelina I.
    Straughn, J. Michael, Jr.
    Buchsbaum, Donald J.
    [J]. GYNECOLOGIC ONCOLOGY, 2013, 131 (03) : 772 - 779
  • [3] Imatinib potentiates antitumor T cell responses in gastrointestinal stromal tumor through the inhibition of Ido
    Balachandran, Vinod P.
    Cavnar, Michael J.
    Zeng, Shan
    Bamboat, Zubin M.
    Ocuin, Lee M.
    Obaid, Hebroon
    Sorenson, Eric C.
    Popow, Rachel
    Ariyan, Charlotte
    Rossi, Ferdinand
    Besmer, Peter
    Guo, Tianhua
    Antonescu, Cristina R.
    Taguchi, Takahiro
    Yuan, Jianda
    Wolchok, Jedd D.
    Allison, James P.
    DeMatteo, Ronald P.
    [J]. NATURE MEDICINE, 2011, 17 (09) : 1094 - U99
  • [4] Phase 1, open-label, dose-escalation, and pharmacokinetic study of STAT3 inhibitor OPB-31121 in subjects with advanced solid tumors
    Bendell, Johanna C.
    Hong, David S.
    Burris, Howard A., III
    Naing, Aung
    Jones, Suzanne F.
    Falchook, Gerald
    Bricmont, Patricia
    Elekes, Agnes
    Rock, Edwin P.
    Kurzrock, Razelle
    [J]. CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2014, 74 (01) : 125 - 130
  • [5] A phase II study of sunitinib in patients with recurrent epithelial ovarian and primary peritoneal carcinoma: an NCIC Clinical Trials Group Study
    Biagi, J. J.
    Oza, A. M.
    ChalChal, H. I.
    Grimshaw, R.
    Ellard, S. L.
    Lee, U.
    Hirte, H.
    Sederias, J.
    Ivy, S. P.
    Eisenhauer, E. A.
    [J]. ANNALS OF ONCOLOGY, 2011, 22 (02) : 335 - 340
  • [6] p38 mitogen-activated protein kinase regulates canonical Wnt-β-catenin signaling by inactivation of GSK3β
    Bikkavilli, Rama Kamesh
    Feigin, Michael E.
    Malbon, Craig C.
    [J]. JOURNAL OF CELL SCIENCE, 2008, 121 (21) : 3598 - 3607
  • [7] Reduction of hypoxia-induced angiogenesis in ovarian cancer cells by inhibition of HIF-1 alpha gene expression
    Bryant, Christopher S.
    Munkarah, Adnan R.
    Kumar, Sanjeev
    Batchu, Ramesh B.
    Shah, Jay P.
    Berman, Jeremy
    Morris, Robert T.
    Jiang, Zhong L.
    Saed, Ghassan M.
    [J]. ARCHIVES OF GYNECOLOGY AND OBSTETRICS, 2010, 282 (06) : 677 - 683
  • [8] Characterization of LY2228820 Dimesylate, a Potent and Selective Inhibitor of p38 MAPK with Antitumor Activity
    Campbell, Robert M.
    Anderson, Bryan D.
    Brooks, Nathan A.
    Brooks, Harold B.
    Chan, Edward M.
    De Dios, Alfonso
    Gilmour, Raymond
    Graff, Jeremy R.
    Jambrina, Enrique
    Mader, Mary
    McCann, Denis
    Na, Songqing
    Parsons, Stephen H.
    Pratt, Susan E.
    Shih, Chuan
    Stancato, Louis F.
    Starling, James J.
    Tate, Courtney
    Velasco, Juan A.
    Wang, Yong
    Ye, Xiang S.
    [J]. MOLECULAR CANCER THERAPEUTICS, 2014, 13 (02) : 364 - 374
  • [9] Modulation of p38 MAPK signaling enhances dendritic cell activation of human CD4+ Th17 responses to ovarian tumor antigen
    Cannon, Martin J.
    Goyne, Hannah E.
    Stone, Pamela J. B.
    MacDonald, Laura J.
    James, Lindsey E.
    Cobos, Everardo
    Chiriva-Internati, Maurizio
    [J]. CANCER IMMUNOLOGY IMMUNOTHERAPY, 2013, 62 (05) : 839 - 849
  • [10] Impeding Macrophage Entry into Hypoxic Tumor Areas by Sema3A/Nrp1 Signaling Blockade Inhibits Angiogenesis and Restores Antitumor Immunity
    Casazza, Andrea
    Laoui, Damya
    Wenes, Mathias
    Rizzolio, Sabrina
    Bassani, Nicklas
    Mambretti, Marco
    Deschoemaeker, Sofie
    Van Ginderachter, Jo A.
    Tamagnone, Luca
    Mazzone, Massimiliano
    [J]. CANCER CELL, 2013, 24 (06) : 695 - 709